In fact, the ratio ApoB:ApoA-I may be the best predictor of risk of atherosclerosis and likewise the optimal measure to assess new lipid-lowering medication, as treatment regimens that lower ApoB are likely to be most effective in reducing plaque formation. Here, APOB is linked to atherosclerosis.